Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Sir William Dunn School of Pathology, together with colleagues from across Oxford, have successfully obtained a structure of the surface layer from Gram-negative bacteria, bound to the cell membrane via long sugars called lipopolysaccharide or endotoxin, by applying novel electron tomography techniques.

This proof-of-concept study shows how structural biology is entering a new era, where it is possible to resolve atomic structures directly inside their native environment in cells.

DunnCellpaper2.jpgGram-negative bacteria are widespread, and include several human pathogens, causing antibiotic resistant infections, which are difficult to treat. Most bacteria are surrounded by a protective surface layer made of proteins, termed ‘S-layer’. Due to their copy numbers on prokaryotes (bacteria and archaea), S-layer proteins are the most abundant class of proteins on earth. Despite their abundance and importance, atomic resolution details of S-layers are not available, and S-layers remain an under-explored area of fundamental biology.

This recent study by Tanmay Bharat’s group, in collaboration with Carol Robinson’s group in Department of Chemistry and Phillip Stansfeld’s group in Department of Biochemistry, shows the power of integrated structural biology in resolving atomic structures from cells, and deducing complex biological mechanisms in situ. In addition to the surface layer structure reported, this study reports the native structure and arrangement of endotoxin or lipopolysaccharide, which is a ubiquitous molecule in Gram-negative bacteria, including several human pathogens, as it is found on cells.

This study will have important implications not only in the field of prokaryotic biology related to S-layers, but also in the future of structure-based drug design.

Similar stories

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.